STOCKS TELEGRAPH

Tag: TDOC

Is it the Best Time to Buy the Long Beaten Down Stock, Teladoc Health Inc. (TDOC)?

The pandemic, while wreaking havoc across the world, brought about a revolutionary shift towards remote working and opportunities. The initial phases of the outbreak thus handed over massive benefits to certain stay-at-home type stocks like Teladoc Health Inc. (TDOC ).

The leading provider of virtual healthcare services stock shot up to nearly $300 a share in early 2021, but it currently sits at just $33.75 per share, a staggering decline of over 75%. The high-flying days witnessed by the pandemic winner have come to halt and investors are disappointed in the adverse price action as of lately. While the world shut down and dealt with the fear of the virus, TDOC provided high-quality healthcare solutions to them inside the safe boundaries of their homes. But the stock is currently down over 60% just in 2022 as the world once again enters a dark phase of economic instability while companies focus on bringing their physical work functionality post the pandemic hype.

Amid the downfall of TDOC came another lackluster news of huge losses in the recent quarterly earnings, despite revenue improvement and overall performance in such tumulus times. While the loss was linked to its Livongo acquisition’s goodwill impairment, investors were still widely disappointed as the company cut down its full-year outlook owing to the impairment charges and certain other reasons. While most view TDOC as a failed company, the truth cannot be farther from it, as all is not lost and the telehealth industry is expected to continue booming. So, is it the best time to buy TDOC or not? Let’s have a look.

TDOC’s Latest Earnings

Source: Investor Junkie

The Major Highlight

The headline from the company’s Q1 2022 earnings shared at the end of April was its net loss of $6.7 billion. This figure came against the year earlier’s loss of just $200 million. This huge swing year-over-year came from a goodwill impairment charge related to the company’s 2020 acquisition of Livongo, which is a chronic condition management company. The impairment charge was a result of the sustained decline of TDOC share price in addition to various market-based factors.

While a goodwill impairment charge appears as an operating loss on the income statement of a company as well as a decrease on the balance sheet, it is essentially the value of intangible aspects of an acquired business. Given that it’s not a cash expense, it is added back to the cash flow statement, thus, not impacting the overall cash flows of the company. But despite this, the huge impairment charge came as a shocker to investors as the net loss widened to $41.58 a share against the year ago’s $1.31 per share. However, the adjusted loss per share of 47 cents was still narrower than the expected 55 cents.

Earnings Summary

TDOC’s overall earnings results mostly came in line with its Q1 guidance, with most metrics exceeding or near the top end of the guidance. Revenue stood at $565.4 million (inline) with a 25% YOY increase from $453.7 million. However, the revenue did fall below the expectations of $569 million for the quarter.

Moreover, the total U.S. paid memberships, fee-only access, and total visits, all exceeded or met the top end with respective YOY growth of 5%, 14%, and 35%. The metrics were $54.3 million, 25.2 million, and 4.5 million for the quarter, respectively. The adjusted EBITDA also came near the top end of the guidance at $54.5 million for Q1 2022.

TDOC’s 2022 Outlook

According to the company, TDOC’s direct-to-consumer mental health service, BetterHelp has been performing below the expectations. This, on top of the huge impairment charge, led the company to cut back on its 2022 guidance. Therefore, the revised guidance has the revenue pegged at $2.4-$2.5 billion against the previous $2.55-$2.65 million. Adjusted EBITDA is now expected to be $240-$265 million against $330-$355 million and net loss $43.50-$43.00 per share against $1.60-$1.40 a share.

On the other hand, total U.S. paid memberships remain unchanged at 54-56 million, while fee-only access is also nearly the same at roughly 25 million. Furthermore, total visits for 2022 dropped just 0.5 million in the revised guidance to 18.5-19.5 million against 18.5-20.0 million.

The Takeaway

Even with the guidance reduction, TDOC is still looking to grow by 20% in its revenue, and being a leader in its space, it could lead to outsized gains over the long term. The stock maintains a “HOLD” ranking from Zacks, with most deeming it a good long-term growth stock as the company delivered nice YOY improvement despite the macroeconomic conditions and decreased hype in the market. The company has continued delivering YOY improvement in its revenue and most key metrics while remaining on top of its space.

Additionally, the telehealth market is expected to continue growing with a CAGR of 32% by 2028. With its continued expansion through its acquisitions of BetterHelp, Healthiest You, and Livongo and YOY revenue improvement while being a market leader, TDOC is poised for some nice gains amid the growing industry.

However, risks exist as the wider market continues its downfall amid macroeconomic instability and increasing competition. Buying the stock at the present brings the opportunity of saving much with its beaten-down price, as Cathy Wood did the same by buying over $20 million worth of TDOC as it tanked after the earnings. While the stock might not be a “BUY” from analysts at the moment, it is ridiculously cheap right now with a bullish long-term outlook from most. The opportunity in TDOC extends long beyond just a pandemic play.

May 16, 2022
Teladoc Health Inc. (TDOC) shares Slump on a Much Wider Loss & Slashed Outlook

The remote healthcare provider, Teladoc Health Inc. (TDOC ) shares slumped in the after-hours on April 27 following its latest earnings. The company’s Q1 2022 earnings had investors spin a sell-off which led to a decline of 36.83% in the session. Thus, the stock tumbled down to a price of $35.37 apiece in the after-hours while 6.74 million shares exchanged hands. This steep decline came after a slight loss of 3.08% in the prior session.

Source: FreshBooks

TDOC’s Q1 2022 Analysis

The company’s Q1 2022 earnings took a harsh hit from a non-cash goodwill impairment charge of $6.6 billion. Associated with the value loss of assets, not many details were shared about the impairment charge. However, it caused the company’s net loss to reach $6.67 billion with a loss per share of $41.58. Analysts were expecting a loss of just $0.60 per share while the prior year’s loss stood at $1.31 per share.

Moreover, TDOC did show a 25% YOY improvement in its revenue which reached $565.4 million in the first quarter of 2022. But despite the YOY growth, revenue also fell short of the expected $568.7 million for the quarter.

Slashed Outlook

Given the huge impairment charge and much deeper-than-expected loss, on top of market dynamics, the company has significantly slashed its outlook for the full-year 2022. The new projections have the revenue ranging from $2.4 billion to $2.5 billion against the previous $2.55-$2.65 billion.

Furthermore, the EBITDA was revised from $18-$48 million to a negative $7-$52 million for the year. The net loss is expected to result in negative earnings of $43.50 to $43.00 per share.

TDOC’s CEO, Jason Gorevic deemed the higher advertising costs and lower-than-expected yield of marketing spend as well as elongated cycles of employer and health plans to be added reasons for the revised outlook.

What Happened with TDOC?

TDOC was one of the pandemic darlings as it accumulated immense gains from the digital transformation amid the outbreak. With the uptick in demand due to the pandemic, the stock also saw a huge upsurge. But the post-pandemic reality hit it hard as its shares fell after the speculative bubble busted. The company is now facing many headwinds and its growth has declined as well. However, the market for telehealth is bullish with an increase of 32% expected by 2028. If the company breaks free from the current headwinds, with the growing scope of telehealth, it would have a bullish future as well.

Conclusion

With a much deeper-than-expected loss on top of a revenue miss, TDCO stock suffered a blow in the after-hours on Wednesday. The company’s slashed outlook was another reason for the steep decline of the stock.

April 28, 2022
Teladoc Health, Inc. (TDOC) stock surged in the Current Market; here is why?

Teladoc Health, Inc. (TDOC) gained in the current market after announcing its partnership with Amazon Alexa. TDOC values at $77.05, gaining more than 9% compared to Friday’s closing price. The stock closed at $70.73 at the end of the last trading session. The stock volume traded in the last trading session was around 4.71 million shares. The current market cap of the company is around $12.17 billion.

TDOC partners with Amazon Alexa

Teladoc Health, Inc. (TDOC) announced in a press release today that they have entered into a joint venture with Amazon to launch Teladoc Health on Alexa. With this deal, Alexa users in the US will be able to connect with Teledoc care providers. The service will provide 24/7. This is a very new experience of the company with Amazon Alexa, due to which users will be able to reach virtual health care support via Teledoc on the supported Echo devices. These devices include Echo, Echo Dot, and Echo Show. In the first phase of the launch, they will provide audio support, and soon video support will also be launched.

TDOC CPO Remarks

Teladoc Health’s chief product officer Donna Boyer said the partnership with Amazon is another step toward lowering healthcare costs. We are giving a new and easy option for people to interact with a doctor by combining our virtual first care experience with Echo devices. We are reaching customers where they are to keep members happy.

TDOC Recently Announced Fiscal 2021 Results

Its revenue was around $2.3 billion in fiscal 2021, increasing more than 86%. The company is expanding its operation, which is why its profitability was negative. That is why the company reported a net loss of $428.8 million.

For this reason, the corporation has published its financial projections in light of the pandemic uncertainty. Revenues of $565 million to $571 million are expected in the first quarter of 2022, according to TDOC. According to the company’s estimates, it will earn between $2.55 million and $2.65 billion in the next fiscal year. With a loss per share expected to range from $$0.60-$0.50 in Q1, they foresee a $$1.60-$1.40 loss per share for the whole fiscal year of 2022.

Conclusion

The current deal with Amazon Alexa will bring more customers to the company. It will also increase its brand positioning and get closer to its target audience.

February 28, 2022
Teladoc Health, Inc. (TDOC) stock declined in the after-hours; here is why?
Teladoc Health, Inc. (TDOC) declined in the after-hours market after announcing its fourth quarter and fiscal 2021 results. TDOC values at $62.16, losing more than 4.8% compared to yesterday’s closing price. The stock closed at $65.30 at the end of the last trading session. The stock volume traded in the last trading session was around 4.21 million shares. The current market cap of the company is around $10.45 billion.

TDOC: Key Financials
- Teladoc Health, Inc. (TDOC) revenue in Q4 2021 was $554.2 million. It is a gain of more than 45% compared to the revenue of Q4 in 2020. The Q4 2020 revenue was $383.3 million.
- Fiscal year revenue was $2.03 billion, and it is an increase of more than 86% compared to the revenue in fiscal 2020. The fiscal 2020 revenue was $1.09 billion.
- The company’s net loss in Q4 2021 was around $11 million. The net loss was $394 million in Q4 2020.
- TDOC net loss in fiscal 2021 was around $428.8 million, compared to the net loss of $485.1 million in fiscal 2020.
- The Q4 2021 loss per share was $0.07.
- For fiscal 2021, the loss per share was $2.73.
TDOC CEO’s Remarks

Teladoc Health CEO Jason Gorevic said that Teladoc Health made excellent progress in 2021 in providing complete whole-person care. We met our goals, earned our clients’ trust, and connected millions of people to exceptional treatment. We will always be the first choice for customers seeking healthcare.

Teladoc Health’s extensive virtual care services link chronic, primary, acute, and specialist care patients. We saw substantial growth and penetration in various crucial areas of our firm using BetterHelp direct-to-consumer and MyStrength Complete B2B2C strategies for proper treatment at the perfect time.

TDOC 2022 Outlook

The company has provided its expected financial numbers in light of the uncertain situation of a pandemic. TDOC expects revenue between $565 million to $571 million in the first quarter of 2022. For fiscal 2022, the company expects revenue between $2.55 million to $2.65 billion. They expect a loss per share of $0.60 to $0.50 in Q1, and for fiscal 2022 it anticipates a loss per share of $$1.60 to $1.40.

Conclusion

The company’s revenue guidance shows a gain of around 25 to 30%. The company is focusing on increasing its market share and reaching more target audiences. That is why its revenue is increasing but is not profitable yet. They are focusing on the company’s growth, and profitability is the later part of such strategies.
February 23, 2022
Top 3 Health Care Stocks that can attract investors in 2021

Health care is a trillion-dollar industry because health is a global need. A trillion-dollar industry means plenty of companies making millions or billions of dollars annually in the health sector. With the surge of COVID-19, this industry has attracted plethora of investors to invest in healthcare stocks but many of them find it difficult to select the right stock at the right time. This is because many companies have claimed that they are working on vaccines and related products to cope with COVID-19 but only a few of them have found their way to commercialize their products. One should consider the fact that only COVID-19 is not the opportunity to invest in stocks but there are other health issues that demand a great amount of interest. So, investors need to do a large amount of homework before investing in any stock. Here are the few health care stocks that can attract investors in 2021.

Eli Lilly And Co (NYSE:LLY)

Eli Lilly and Company (LLY) is an American Pharmaceutical company that focuses on discovering, developing, manufacturing, and commercializing drugs for the cure of various kinds of diseases. The company is doing research and production in many nations and 120 countries are using its products.

Eli Lilly Generated handsome revenue in 2020 through the sales of its top products which include Trulicity (Diabetes medicine), Basaglar (Insulin product), and Jardiance (Oral Diabetes drug). Trulicity generated $3.6 billion revenue in the first three quarters of 2020 with a rise of 22%. Similarly, Basaglar generated 842$ million revenue with a rise of 5% and Jardiance showed a rise of 24% with 840$ million income.

The company has got positive results in phase 2 clinical trial of one of its potential drugs for Alzheimer’s disease called donanemab. More than 5 Million Alzheimer’s patients exist in the U.S and still, there is no approved drug for the cure. Still, donanemab has a long way to go for approval but investors can monitor its progress.

The company reported on Tuesday that its late-stage coronavirus treatment trial which includesBamlanivimab (LY-CoV555) 2800 mg and Etesevimab (LY-CoV016), has reduced the riskof death in serious patients and hospitalization by 70% which is pointing out the bright future of the company and investors in terms of revenue.

Hence Lilly has a good chance to outperform in the future due to its revenue growth, solid stock price performance, and good cash flow from operations.

Teladoc Health Inc (NYSE:TDOC)

Teladoc Health, Inc. (TDOC) is a virtual healthcare company playing a lead role in providing the services of diagnosis, treatment recommendation, and prescription through mobile phones and video consultations. The current pandemic situation is suitable for the company when people do not bother to go out of their homes unnecessarily. The company is getting fame day by day due to its best virtual health care services in remote areas and attracting institutional investors to invest in it.

Though Teladoc has not revealed the 2020 report but rough estimates show that it has now more than 50 million members, facilitated more than 10 million visits, and generated about 1.1$ billion revenue in 2020 which is almost double than the previous year. Currently, many companies are providing Teladoc’s health care services to their employees which is expecting to grow in the future. Teladoc’s recent acquisition of Lovingo Health is also creating a more positive vibe for investors.

CVS Health Corp (NYSE:CVS)

CVS Health Corporation (CVS) is an integrated pharmacy healthcare service provider company. It offers pharmacy benefit management plans, health plans, prescription drug plans, and serves the government as well as private employees of many companies. It possesses nearly 10000 drug stores and1100 Minute Clinics in the U.S.The company is playing a key role in COVID-19 testing and is contributing a lot in the vaccination campaign as it has performed nearly 10 million coronavirus tests and 700,000 vaccinations. The company is currently handling 10% of coronavirus vaccination in the U.S and can vaccinate 25 million people per month.

CVS is not just relying on COVID vaccination but also fighting against influenza by vaccinating people. The company generated $67 billion in the 3rd quarter of 2020 with a rise of 3.5% in its sales. Moreover, the company possesses more than 23 million health insurance members nationwide. Thanks to Aetna, a CVS subsidiary, which generates more than $18.5 billion per quarter in health insurance fees.

The company is currently in a good position and has ample profit to sustain its dividend. Its shares are expecting to outperform in 2021 due to active participation in COVID-19 vaccination in the U.S.It can be a good choice for dividend as well as growth investors.

January 27, 2021
Early Morning Vibes: The 4 Best Stocks To Buy Now
On January 19, American stock indexes finished trading in the green zone. The S&P 500 Index rose 0.81% to 3799 points, the NASDAQ rose 1.53%, the Dow Jones added 0.38%. The optimism was driven by a call for Congress, Janet Yellen, who will become the next finance minister, to increase fiscal stimulus by raising government spending. The tech sector emerged as one of the top gainers with 1.31% as Janet Yellen opposed a sharp increase in corporate taxes.

Corporate news
- Investment bank Goldman Sachs (GS: -2.3%) showed strong results, but management was cautious in forecasting gains from trading.
- General Motors (GM: + 9.8%) entered into a partnership agreement with Microsoft (MSFT: + 1.8%) to commercialize electric vehicles with autopilot function.
- Lithium Americas (LAC: + 30.6%) has been cleared by the Bureau of Land Management to mine lithium in Nevada.
Today, global stock markets are showing mixed dynamics. The news background is mostly calm. Investors are focusing on the inauguration of Joe Biden, who will become the 46th President of the United States. In the first hours and days as head of state, Biden plans to repeal a number of Donald Trump’s decrees related to climate policy, immigration, and a number of other aspects. What really matters for the stock market will be decisions related to the fight against COVID-19. It is expected that Biden will oblige citizens to wear masks on federal sites and establish additional sanitary rules. In the first 100 days of his term, the new head of state expects that 100 million people will be vaccinated against the coronavirus. Investors will watch to see how successfully this plan is implemented.

The epidemiological situation in the United States is gradually improving, which has a positive effect on the mood of market participants. The number of patients hospitalized with coronavirus infection fell to 123.8 thousand from a historical high of 132.5 thousand, reached two weeks earlier. Probably, the peak loads on US hospitals have been left behind. In the near future, volatility across sectors and industries will increase due to the publication of quarterly reports. Investor expectations are generally positive, but management’s forecasts for 2021 will be critical.

Meanwhile, the Freedom Finance Sentiment Index climbed to 58 out of 100. The index reflects market participants’ hope for a global economic recovery in 2021. Concerns about the negative impact of the coronavirus pandemic are weakening thanks to the prospect of mass vaccinations.

Technical picture

Technically, the S&P 500 is still prone to short-term consolidation. On the eve of the broader market index showed a sharp rebound from the level of 3750 points, signaling the continued strength of buyers. Technical indicators are a mixed bag. In case of confident overcoming of the historical maximum at 3827 points, the S&P 500 will continue its upward movement within the equidistant channel.

Today Top Movers

BEST Inc (BEST), a trucking company, soared about 12.20% ‎at $2.30 in pre-market ‎trading Wednesday on a possible deal with Alibaba Group. ‎ ‎‎

‎Aikido Pharma Inc (AIKI) share price jumped 15.45% to $1.27 during early morning ‎trading session on ‎Wednesday.‎‎‎ ‎‎

‎PC-Tel Inc (PCTI) stock ascended 26.58% at $11.24 in the pre-market trading today after declaring a development partnership with Zeem Solutions.‎‎ ‎‎

‎Sundial Growers Inc (SNDL) gained over 2.90% at $0.71 in pre-market ‎trading on Wednesday.‎‎

Top Upgrades & Downgrades

UBS turned bullish on Netflix Inc. (NFLX), upgrading the stock to “Buy” and assigning a $650.0 price target, representing potential upside of 29.54% from Tuesday’s close.

The Boeing Company (BA) has won the favor of Berenberg’s equity research team. The firm upgraded the shares from Sell to Hold and moved their price target to $215.0, suggesting 2.06% additional upside for the stock.

Polaris Inc. (PII) received an upgrade from analysts at BMO Capital, who also set their one-year price target on the stock to $136. They changed their rating on PII to Outperform from Market Perform in a recently issued research note.

Earlier Wednesday BTIG reduced its rating on Beyond Meat Inc. (BYND) stock to Neutral from Buy.

Piper Sandler analysts reduced their investment ratings, saying in research reports covered by the media that its rating for Global Blood Therapeutics Inc. (GBT) has been changed to Neutral from Overweight and the new price target is set at $50.

Analysts at Piper Sandler downgraded ShockWave Medical Inc. (SWAV)’s stock to Neutral from Overweight Wednesday.

Latest Insider Activity

IHS Markit Ltd. (INFO) EVP, CFO Gear Jonathan announced the sale of shares taking place on Jan 19 at $87.50 for some 4,000 shares. The total came to more than $0.35 million.

Teladoc Health Inc. (TDOC) Head of Research & Development WANG YULUN sold on Jan 14 a total of 243,768 shares at $226.66 on average. The insider’s sale generated proceeds of almost $1.81 million.

Orgenesis Inc. (ORGS) Director SIDRANSKY DAVID declared the purchase of shares taking place on May 20 at $6.98 for some 10 shares. The transaction amount was around $70.

Old Republic International Corporation (ORI) Director KOVALESKI CHARLES J bought on Jan 13 a total of 10,346 shares at $18.74 on average. The purchase cost the insider an estimated $4,685.

Important Earnings

Top US earnings releases scheduled for today include Morgan Stanley (NYSE: MS). It will announce its Dec 2020 financial results. The company is expected to report earnings of $1.27 per share from revenues of $11.54B in the three-month period.

Analysts expect U.S. Bancorp (NYSE: USB) to report a net income (adjusted) of $0.95 per share when the bank releases its quarterly results shortly. Revenue for the fiscal quarter ended Dec 2020 is predicted to come in at $5.82B.

Kinder Morgan Inc. (KMI), due to announce earnings after the market closes today, is expected to report earnings of $0.24 per share from revenues of $3.05B recently concluded three-month period.
January 20, 2021
Top Telehealth Stocks To Watch In January 2021

Telehealth companies help people see medical professionals remotely through either the phone or video calls. And since the demand for healthcare with elements of social distancing increased during the pandemic, telemedicine services also saw an increase in demand. In the United States, when Congress passed an emergency fund of $8.3 billion, it also loosened certain rules on the use of telehealth services in the U.S. Medicare program. A lot of companies have branched into telehealth but only trade over the counter or are privately owned, except for Teladoc Health which trades on the New York Stock Exchange and has outperformed the broader market and has a market value of $12.2 billion.

Teladoc Health Inc (NYSE: TDOC)

Teladoc Health Inc (TDOC)‎ is one of the best telehealth stocks on Wall Street and benefited from the entire Covid pandemic ordeal since virtual healthcare became a big thing. The company gives virtual healthcare services to a wide range of stakeholders and its revenue more than doubled since then. Teladoc Health managed to close the third quarter last year with the $18.5 billion acquisition of its rival Livongo in October.

In 2020, TDOC’s stocks began to look pricey because they had more than doubled up. It is a compelling growth story within the healthcare sector and is bound to bring in new investors over the years. It is already dubbed as a Strong Buy by 13 of the 27 analysts tracking for the S&P Global Market Intelligence.

American Well Corp (NYSE: AMWL)

American Well Corp (AMWL)‎ is a top-notch telemedicine company based in the United States and is rated 885 out of 1,000 which is higher than the 856 average in the industry. Amwell is part of 55 health plans at the moment and it used by nearly 36,000 employers. But the situation created by the pandemic proved to be extremely profitable for the company as seen in the visits to its platform since 2006 having been 5.6 million out of which 2.9 million of those visits happened till the middle of 2020.

Its revenue increased by 77 per cent in the first half of 2020 by $122.3 million and its monthly visit volumes also saw a more than fourfold increase. In August, it also succeeded in securing a $100 million investment from Google, and much of that will go towards research and development and also in innovating the platform. AMWL is currently capitalized with $831.6 million in cash and investments and since September its stock is up by 70 per cent.

M3

M3 has been a global leader in telehealth in Japan and overseas. It is backed by Sony and initially began as a traditional operator of medical websites but it then used its acquisitions to become a provider of online medical information and telehealth. Much of M3’s revenue comes from the information it makes available to its academics, patients, and doctors. But that still makes it very profitable with a market capitalization of more than $60 billion. Its stock has been tripling over the past year as its capabilities have made it a strong stock and even the best emerging telehealth stock in the market.

During the pandemic it gained 72 per cent for the year to date and it is predicted that with its outsized growth rate if it had been in the S&P 500, it would have been the top fifth index of the most expensive stocks.

January 5, 2021
13 Trending Stocks in Health Information Services Industry

As investors weighed the stimulus vote of Monday against the emergence of a new ‎coronavirus strain ‎in the UK, US equities ended mixed on Tuesday. ‎

The Senate approved the measure Monday night after months of negotiations over ‎additional fiscal ‎support. The bill funds the government through September 30 and includes ‎a new stimulus of $900 ‎billion. Also, the package includes $300 in additional federal ‎unemployment benefits and $600 in direct ‎payments.  ‎

Some of the key players in the Health Information Services sector were:  ‎‎

NantHealth Inc. (NASDAQ:NH) shares were trading up 21.50% at $3.56 at the ‎time of writing on Tuesday.‎

NantHealth Inc. (NASDAQ:NH) share price went from a low point around $0.92 ‎to briefly over $6.60 in past 52 weeks, though shares have since pulled back to $3.56. NH market cap ‎has remained high, hitting $427.88M at the time of writing, giving it price-to-sales ratio of more than ‎‎5.

‎If we look at the recent analyst rating NH, Canaccord Genuity reiterated ‎coverage on NH shares with a Buy rating and a $3.75 price target, which implies ‎room for 0.19% upside momentum this year.

HMS Holdings Corp. (HMSY) last closed at $36.58, in a 52-week range of $18.19 ‎to $36.75. The company recently reported an agreement with Veritas Capital-backed Gainwell ‎Technologies, whereby Gainwell will acquire HMS. Analysts have a consensus price target of ‎‎$35.09.

Teladoc Health Inc. (TDOC) stock soar by 3.15% to $206.04. The most recent ‎rating by Evercore ISI, on December 22, 2020, is at an In-line.

American Well Corporation (NYSE:AMWL) Shares headed rising, higher as much ‎as 5.90%. The most recent rating by Stifel, on December 18, 2020, is at a Hold.

Veeva Systems Inc. (NYSE:VEEV) rose 5.76% after gaining more than $15.61 on ‎Tuesday. Veeva reported on December 15, 2020, that Integra LifeSciences has selected Veeva Vault ‎CDMS for clinical data management. ‎

Change Healthcare Inc. (CHNG) last closed at $18.83, in a 52-week range of ‎‎$6.18 to $18.70 following the announcement of successful introduction of its first cloud-based medical ‎tools for radiologists and other specialties along with its roadmap to help healthcare organizations ‎begin their migration of medical imaging to the cloud. Analysts have a consensus price target of ‎‎$20.39.

GoodRx Holdings Inc. (GDRX) stock soar by 3.49% to $48.32 after announcing ‎recognition from workplace culture site Comparably for its company culture and leadership. The most ‎recent rating by RBC Capital Mkts, on November 19, 2020, is at an Outperform.

Allscripts Healthcare Solutions Inc. (NASDAQ:MDRX) Shares headed rising, ‎higher as much as 2.15%. The company announced on December 17, 2020, that it is dedicating ‎extensive resources to ensure its clients are prepared to maximize functionality within its solutions to ‎respond to the COVID-19 pandemic. The most recent rating by Argus, on November 11, 2020, is at a ‎Buy.

HealthEquity Inc. (NASDAQ:HQY) rose 2.27% after gaining more than $1.51 on ‎Tuesday. The company reported on December 8, 2020, that revenue for the third quarter ended ‎October 31, 2020 of $179.4 million grew 14% compared to $157.1 million for the third quarter ended ‎October 31, 2019.

‎Cerner Corporation (CERN) last closed at $77.38, in a 52-week range of $53.08 to ‎‎$80.90. The firm on December 16, 2020 revealed an agreement to acquire health division of Kantar. ‎Analysts have a consensus price target of $78.23.

‎1Life Healthcare Inc. (ONEM) stock soar by 3.97% to $43.26. The most recent ‎rating by Credit Suisse, on October 30, 2020, is at an Outperform.

‎So-Young International Inc. (NASDAQ:SY) Shares headed falling, lower as much ‎as -7.41%. The most recent rating by Deutsche Bank, on April 23, 2020, is at a Buy.

‎Schrodinger Inc. (NASDAQ:SDGR) rose 0.85% after gaining more than $0.7 on ‎Tuesday.

December 23, 2020